Apr 29th, 2009 - MarketWatch
Related topics:
BOSTON (MarketWatch) -- Dendreon Corp. led drug stocks higher in afternoon trading Wednesday as shares of the biotech group rocketed on results from a positive study for its prostate cancer therapy Provenge.
The Amex Pharmaceutical Index was up 1.2% to 237.63 and the Amex Biotechnology Index climbed 2.9% to 654.61. The Dow Jones Industrial Average (XX:DJII: news , chart , profile ) advanced almost 200 points to 8,214.
Related stories:
Dendreon Drug Clears Difficult Hurdle, But Others Remain
Apr 29th, 2009 - Wall Street Journal
NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) has cleared a significant hurdle in bringing its controversial prostate cancer treatment Provenge to market, but obstacles remain before the drug gets launched. Provenge could be a blockbuster drug...
Seaspan, Dendreon: Biggest Price Decliners (SSW, DNDN)
Apr 28th, 2009 - Wall Street Journal
Seaspan Corp. topped the list of Biggest Percentage Price Decliners among common stocks on the New York Stock Exchange at the close on Tuesday. See the full list . Dendreon Corp...
Glaxo, Novavax, other drug stocks leap due to swine flu
Apr 27th, 2009 - USA Today
As concern spread Monday about a swine flu virus outbreak, investors saw opportunity in shares of companies that make or hope to make anti-flu drugs. Britain's GlaxoSmithKline...
Niche antiviral drugmakers rocket on flu news
Apr 27th, 2009 - MarketWatch
BOSTON (MarketWatch) -- Shares of niche makers of antiviral products and vaccines saw shares rocket in early trading Monday on news that the world could be facing a global pandemic of the swine flu virus.
BIOTECH STOCKS Merck, Schering, Forest lead drug stocks south
Apr 21st, 2009 - MarketWatch
BOSTON (MarketWatch) -- Drug stocks headed south Tuesday, led by Forest Laboratories, Merck & Co. and Schering-Plough Corp., while the broader market regained ground...
